[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"typhoid-fever\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:typhoid-fever":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642723","comparison-of-single-versus-combination-drug-therapy-in-extensively-drug-resistant-salmonella-typhi-in-terms-of-time-to-defervescence-100642723",false,"NCT07641348","COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE","COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG-RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE","* Inclusion Criteria\n\n  1. Children aged 2-16 years\n  2. Culture-confirmed XDR typhoid fever (resistant to first-line agents, fluoroquinolones, and third-generation cephalosporins)\n  3. Admitted to Children's Hospital \\& Institute of Child Health, Lahore\n\nInformed consent obtained from parent\u002Fguardian\n\nExclusion Criteria\n\n1. Age \\\u003C2 years or \\>16 years\n2. Known allergy or contraindication to meropenem or azithromycin\n3. Presence of severe comorbidities (e.g., congenital heart disease, chronic renal failure, immunodeficiency)\n4. Patients already receiving carbapenem or azithromycin therapy prior to enrollment","ALL","2 Years","16 Years",{"count":20,"type":21},94,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial will compare the effectiveness of single-drug therapy (meropenem) versus combination therapy (meropenem plus azithromycin) in children aged 2-16 years diagnosed with extensively drug-resistant (XDR) typhoid fever at the Children's Hospital, Lahore. A total of 94 patients will be enrolled and randomly assigned to either treatment group. The primary outcome is time to defervescence, defined as sustained resolution of fever for more than 48 hours. Secondary outcomes include duration of hospital stay and complication rates. The study aims to provide evidence to guide optimal management of XDR typhoid in pediatric populations.\"",[27],"Typhoid Fever","NOT_YET_RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":21},"2026-07-01",{"date":36,"type":21},"2027-02-01",{"name":38,"class":39},"Iqra Asghar Ali","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100574284","phase-3-zyvac-tcv-bangladesh-study-100574284","NCT06757283","ZyVac-TCV Bangladesh Study","Evaluation of Typhoid Conjugate Vaccine (TCV) Effectiveness Among Bangladeshi Children Using the Test-negative Design","Inclusion Criteria:\n\n* Participant was included in the baseline list of the study population\n* Participants living within the study catchment area at the time of vaccination\n* Parent\u002Fguardian is willing and competent to provide informed consent (if the participant is 11 to 15 years of age, assent will also be sought)\n* Participants aged between 6 months to15 years (i.e. up to 15 years 364 days) at the time of vaccination\n* Apparently healthy (no complaints of febrile illness) on the day of vaccination\n* Parent\u002Fguardian confirms that their child will be willing and be able to comply with study requirements\n\nExclusion Criteria:\n\n* Has knowingly received a typhoid vaccine in the past\n* Known allergy to any vaccine in the past\n* Medical or social reasons that will prevent the participant from conforming to the study requirements as judged by a medical professional\n* Planning to move away from the catchment area within the next 12 months\n* Pregnant at the time of vaccination, as confirmed by a urine test (urine pregnancy test will be done in girls who are married)\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or subjects on any immunosuppressive or immunostimulant therapy\n* Subject participated in another clinical study in the past 3 months",true,"6 Months","15 Years",{"count":52,"type":21},4000,[54],"PHASE3","This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV (purified Vi capsular polysaccharide of Salmonella Typhi conjugated to tetanus toxoid as carrier protein), manufactured by Zydus Lifesciences Limited. The study will be conducted in a closed cohort population among children aged 6 months to 15 years residing in wards 5, 6, 7, 48, 49, 50, 63, 71, and 72 of Dhaka South City Corporation (DSCC). The targeted number of age-eligible children in the study area is \\~92,000 among them \\~60,000 will be vaccinated. A subset of the first 600 consenting participants will be selected by age strata (6 months to \\\u003C2 years, 2-4 years, 5-15 years) for enrollment in the immunogenicity study with an additional three follow-up visits. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data up to day 7 for a subset of active follow-up of the first 600 vaccinated participants. Participants not in this subset will be encouraged to go to the 'Adverse Event Monitoring Cell' at the Maniknagar field office. Data on serious adverse events (SAEs) will be reported for six months after vaccination. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor. Passive surveillance for typhoid fever will be carried out in the Maniknagar field office and Mugda Medical College and Hospital in the catchment area among the age-eligible children.",[57,58,27],"Typhoid Vaccination","Typhoid",[60,61,62,63,64,65],"Conjugate vaccine","Immunogenicity","Safety","Typhoid fever","Bangladesh","Children","2025-02-06",{"date":68,"type":32},"2025-02-07",{"date":70,"type":21},"2025-04-01",{"date":72,"type":21},"2026-05-30",{"name":74,"class":39},"International Centre for Diarrhoeal Disease Research, Bangladesh"]